The 21-valent pneumococcal conjugate vaccine V116 is well tolerated in adults living with HIV and induces immunity to all 21 ...

Phase 2 clinical study titled ‘A Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 study titled ‘A Study to Learn About ...

Infectious disease researchers found the vaccine, used to prevent herpes zoster, or shingles, is also linked to lower risks ...

Several observational analyses suggest higher cardiovascular and dementia risks in those with and without HIV who get ...

Vaccine awareness, safety, and addressing misinformation are all important to improve adherence and public health outcomes, ...

The adult-specific 21-valent pneumococcal conjugate vaccine was well tolerated and immunogenic across all 21 serotypes in patients with HIV infection.

A series of recommended shots that health providers administer to children as they age has been a recent target of President ...

The United States Adult Vaccine Market is projected to soar to US$ 11.10 billion by 2033, up from US$ 6.55 billion in 2024, ...

Eligibility for this vaccination is suddenly a timely question. A senior health editor reports on her real-time experience.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 3 STRIDE-13 trial evaluating CAPVAXIVE® (Pneumococcal 21-valent Conjugate ...

The shingles vaccine may cut dementia risk by up to 33%, per new research. Here, experts explain how it works and what it may ...